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clinical characteristics
The issue of blood lactate in HIV-infected children
treated with antiretrovirals has recently been
addressed.1 Hyperlacticacidemia is increasingly
being recognized as a serious concern among HIV-
infected patients and is fatal in some cases, but
there are no firm data regarding differences by age,
sex, race or exposure to different antiretroviral
therapies or to particular risk factors.2—7 Hyperlac-
ticacidemia and lactic acidosis do occur in both
adults and children, but it is unclear whether
severe lactic acidosis is preceded by a period of
increased plasma lactate level (PLL) and prospec-
tive studies of the prevalence of lactate levels are
lacking.8
The plasma lactate level was evaluated in two
different blood samples taken one year apart (mean
12.4 months, range 7—18 months) in children
attending the infectious diseases clinic at the Uni-
versity of Genoa. The purpose of the determination
after 12 months was to assess the eventual occur-
rence of increased PLL in children with previously
normal values. Children who had altered values at
the first determination had normal or stable values
in the following determination after four to eight
weeks. All patients underwent regular clinic visits
and laboratory assessments every four to eight
weeks and their compliance with antiretroviral
therapy was considered good. PLL was first deter-
mined between 1 January and 31 March 2002 and
then again between 1 January and 31 March 2003.
Fifty-one children (28 males, 23 females) were
evaluated, with amean age of 11.02 years (range 1—
19 years); 49/51 children (27 males, 22 females)
underwent both lactate assessments. According to
CDC staging, 31/51 (61%) patients were sympto-
matic (stage B or C) and 20 (39%) were asympto-
matic (stage A or N). Fat redistribution, identified by
physical signs of central fat accumulation, periph-1201-9712/$30.00 # 2005 International Society for Infectious Diseas
doi:10.1016/j.ijid.2004.07.004eral lipoatrophy or both, was observed at baseline in
14/51 children (27%). Baseline characteristics did
not differ between the two determinations regard-
ing CDC staging and fat redistribution.
Possible risk factors for increased PLL were con-
sidered to be: gender, fat redistribution, CDC stage
and current antiretroviral therapy. In particular,
regimens containing didanosine (DDI), stavudine
(D4T), DDI + D4T, protease inhibitors (PIs) and
DDI + D4T + PI were considered. Plasma lactate
level was considered normal below 2.0 mmol/l.
None of the children showed clinical signs or
symptoms related to hyperlacticacidemia at the
first lactate determination. PLL was increased in
23/51 patients (45%) at the first assessment and in
11/49 (22%) at the second assessment.
At the time of the two blood samples, antiretro-
virals were being administered to 45/51 (88%) and
45/49 children (92%) respectively: nine (18%) and
ten patients (20%) received dual nucleoside reverse
transcriptase inhibitors (NRTI) or a PI-sparing ther-
apy; 36 (70%) and 35 (71%) received a PI-containing
therapy. Mean duration of their current therapy was
27.4 months (range 0—66) and 35.2 months (range
0—77) respectively, while the cumulative time of
exposure to the different antiretrovirals was 80.6
months (range 0—164) and 94.2 months (range 0—
178).
PLL was studied as the primary variable. All the
comparisons between groups were carried out using
the x2 test (Table 1). In both determinations,
increased lactate levels were observed more fre-
quently in females, in patients with more advanced
infection, those affected by lipodystrophy and those
treated with PI and less frequently in those only
treated with NRTIs. An association with duration of
treatment was not found. Increased PLL in the
second sample occurred significantly more fre-
quently in children with previously altered values
(p = 0.039).
Recently, several studies have implicated therapy
with stavudine and/or didanosine as a risk factor fores. Published by Elsevier Ltd. All rights reserved.
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Table 1 Association of plasma lactate levels (PLL) with all considered risk factors.
1st assessment (51 patients)
PLL 1st sample
Total number
of cases
Normal
PLL N
% Increased
PLL N
% p values
PLL 1st sample
Females 23 10 43.5 13 56.5 0.114
Males 28 18 64.3 10 35.7
CDC stage B or C 31 16 51.6 15 48.4 0.383
CDC stage A or N 20 12 60 8 40
Lipodystrophy 14 6 42.9 8 57.1 0.227
No lipodystrophy 37 22 59.5 15 40.5
Antiretroviral 45 24 53.3 21 46.7 0.434
No antiretroviral 6 4 66.7 2 33.3
DDI 19 11 57.9 8 42.1 0.485
No DDI 32 17 53.1 15 46.9
D4T 27 15 55.6 12 44.4 0.572
No D4T 24 13 54.2 11 45.8
DDI + D4T 16 9 56.3 7 43.8 0.570
No DDI + D4T 35 19 54.3 16 45.7
PI 36 18 50 18 50 0.218
No PI 15 10 66.7 5 33.3
DDI + D4T + PI 16 9 56.3 7 43.8 0.570
No DDI + D4T + PI 2nd assessment (49 patients) 35 19 54.3 16 45.7
PLL 2nd sample
Females 22 16 72.7 6 27.3 0.348
Males 27 22 81.5 5 18.5
CDC stage B or C 31 23 74.2 8 25.8 0.357
CDC stage A or N 18 15 83.3 3 16.7
Lipodystrophy 14 7 50 7 50 0.007
No lipodystrophy 35 31 88.6 4 11.4
DDI 23 16 69.6 7 30.4 0.180
No DDI 26 22 84.4 4 15.4
D4T 29 21 72.4 8 27.6 0.248
No D4T 20 17 85 3 15
DDI + D4T 17 12 70.6 5 29.4 0.307
No DDI + D4T 32 26 81.3 6 18.8
PI 35 25 71.4 10 28.6 0.103
No PI 14 13 92.9 1 7.1
DDI + D4T + PI 15 11 73.3 4 26.7 0.450
No DDI + D4T + PI 34 27 79.4 7 20.6
Altered PLL 1st sample 22 14 63.6 8 36.4 0.039
Normal PLL 1st sample 27 24 88.9 3 11.1
DDI: didanosine; D4T: stavudine; PI: protease inhibitor; CDC: Centers for Disease; Control; PLL: plasma lactate level.hyperlacticacidemia or lactic acidosis; in this study,
a correlation with elevated PLL was especially found
with the use of PIs. This study found increased PLL in
treated children and those with lipodystrophy, as is
also described elsewhere.1,9
It has been found that increased PLL does not
appear to be predictive either of consecutivealtered values or of severe hyperlacticacidemia in
HIV-infected children: one patient had fatal lactic
acidosis and her previous PLL was normal.10
Consecutive follow-up and larger cohorts of chil-
dren will allow better identification of the risk
factors for elevated PLL and for hyperlacticacide-
mia.
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